ライフサイエンスコーパス: antitumor

1 terial, antiprotozoal, anti-inflammatory and antitumor.

2 t a long-lived phenotype exhibiting improved antitumor activities into T-cells by transfecting them w

3 irect protein target for the teratogenic and antitumor activities of immunomodulatory drugs such as t

4 Here we review antitumor activities of innate immune cells, mechanisms

5 Antitumor activity (seven partial responses [six confirm

6 sults provide a proof of concept of systemic antitumor activity after intratumoral CD40 triggering wi

7 mouse xenografts revealed that 6OTD exhibits antitumor activity against glioblastoma.

8 and metabolic stability and 39 times higher antitumor activity against hormone-resistant prostate ca

9 nsus androgen response element half-site has antitumor activity against hormone-sensitive prostate ca

10 nstrated a safety therapy profile with broad antitumor activity against solid and hematological malig

11 fies an optimal cell dose with highly potent antitumor activity and a tolerable adverse effect profil

12 cervical cancer, pembrolizumab demonstrated antitumor activity and exhibited a safety profile consis

13 peutics metformin and phenformin, have shown antitumor activity both in vitro and in vivo.

14 ent protein kinase inhibitors with promising antitumor activity but suboptimal aqueous solubility, co

15 yrin micelles (SN-NPM) enhanced the in vitro antitumor activity by 78 and 350 times over single treat

16 phorylation of PTPN12 by CDK2 discharged its antitumor activity by down-regulation of its inhibitory

17 Remarkable antitumor activity by means of objective radiologic resp

18 trate that SIRPalpha blockade induces potent antitumor activity by targeting multiple myeloid cell su

19 g CAd-VECPDL1 with HER2.CAR T cells enhanced antitumor activity compared with treatment with either H

20 tate-specific antigen response rates suggest antitumor activity in a patient subset.

21 1F5hIgG1 had good antitumor activity in all tumor models tested.

22 ylase (HDAC) inhibition has shown remarkable antitumor activity in hematological malignancies, it has

23 ion of MK-1775 and Ex527 induces cooperative antitumor activity in lung cancer xenograft model in viv

24 Purpose Pembrolizumab provides durable antitumor activity in metastatic melanoma, including com

25 er, the Her2 x CD3 BsAb shows potent in vivo antitumor activity in mouse Her2(2+) and Her2(1+) xenogr

26 ive cancer because AKT inhibition has potent antitumor activity in the DLC1-positive transgenic cance

27 Orally administered, 31 achieves significant antitumor activity in the MV4;11 leukemia and MDA-MB-231

28 An antagonistic anti-CCR4 antibody had antitumor activity in the RENCA mouse model of RCC.

29 hway, which results in T-cell activation and antitumor activity in tumor models.

30 ed that (19)F-FCP, like carboplatin, retains antitumor activity in various cell lines.

31 diols and their keto derivatives showed high antitumor activity in vitro against Hek293, Jurkat, K562

32 human colon cancer cells, but also improved antitumor activity in vivo.

33 vaccine treatments consistently negated the antitumor activity of a selective BRAF inhibitor in tumo

34 evelop a combination strategy to enhance the antitumor activity of ALK inhibitor monotherapy in human

35 Purpose We assessed the safety and antitumor activity of avelumab, a fully human anti-progr

36 The costimulation and antitumor activity of CD27 agonistic Abs have been well

37 proliferation, cytokine production, and the antitumor activity of CD8(+) T cells upon antigenic stim

38 In this study, we examined the antitumor activity of CMLD-2, a small-molecule inhibitor

39 nt intratumoral retention that increased the antitumor activity of coadministered temozolomide (TMZ).

40 Both carriers retained antitumor activity of DAS and could form mixed micelles

41 th factor receptor inhibition may complement antitumor activity of immune checkpoint blockade.

42 d drugs in clinical oncology is clear if the antitumor activity of MOv18 IgE in these preclinical exp

43 ety, pharmacokinetics, pharmacodynamics, and antitumor activity of oral BGJ398, a selective FGFR1-3 t

44 However, no study thus far has evaluated the antitumor activity of PD-1-selected TILs in vivo In two

45 We evaluated safety and antitumor activity of pembrolizumab, an anti-PD-1 antibo

46 fect on NK cell infiltration might limit the antitumor activity of the inhibitors.

47 y studies demonstrated that (19)F-FCP has an antitumor activity profile similar to that of the parent

48 35 with systemic anti-PD-1 generates greater antitumor activity than each respective monotherapy.

49 t, compound 14d displayed promising in vitro antitumor activity toward three different prostate cance

50 Enhanced antitumor activity was associated with a unique tumor cy

51 The antitumor activity was evaluated, showing that treatment

52 basic side chains, but the greatest in vivo antitumor activity was found for compounds containing a

53 in a mouse syngeneic model demonstrated high antitumor activity which significantly reduced the tumor

54 ta indicate that the combination has greater antitumor activity without additional safety concerns ve

55 sistant tumors, PS-1001 resulted in enhanced antitumor activity, increased infiltration of macrophage

56 However, antitumor activity, particularly in the context of progr

57 1 antibody, confirming a role for T cells in antitumor activity.

58 exhibits superior selectivity, potency, and antitumor activity.

59 ombine with immuno-oncology drugs to enhance antitumor activity.

60 as a manageable safety profile and promising antitumor activity.

61 CAR) may reduce the side effects and augment antitumor activity.

62 in-like (KIR) receptors and interrupts their antitumor activity.

63 gin, a cytotoxic natural product with potent antitumor activity.

64 rols CD8(+) T memory precursor formation and antitumor activity.

65 an anti-class II MHC antibody abrogated its antitumor activity.

66 tabolism, acceptable toxicity, and promising antitumor activity.

67 ng to type I interferon (IFN) production and antitumor adaptive immunity.

68 (DC) effector function; and (iv) inhibiting antitumor adaptive T cell immunity via the programmed de

69 he potential of DMDD as a safe and effective antitumor agent in the treatment of late-stage breast ca

70 ing lead for development as an antibacterial/antitumor agent.

71 ific use as an antiviral, antibacterial, and antitumor agent.

72 ategies for the design of new RXRalpha-based antitumor agents and drug combinations.

73 first total syntheses of naturally occurring antitumor agents disorazoles A1 and B1 and the full stru

74 low COMPARE correlations with known standard antitumor agents indicate a unique mechanism of action.

75 d total synthesis of the naturally occurring antitumor agents trioxacarcins is described, along with

76 duct biosynthesis, including antibiotics and antitumor agents.

77 The antitumor and anti-metastasis efficacy of CREKA-loaded l

78 T cell activation plays an important role in antitumor and antimicrobial immune responses.

79 derivatives, have been shown to have potent antitumor and metastasis-suppressive effects in multiple

80 rattlesnake, possesses potent antimicrobial, antitumor, and antifungal properties.

81 The antivascular, antitumor, and antimetastatic effects of mpJX-594 were a

82 n tumor cells and indirectly by promoting an antitumor brain microenvironment with a key protective r

83 This virus both induced and maintained antitumor CD8(+) T-cell responses within directly treate

84 ed with oncolytic adenovirus (Ad) expressing antitumor cytokines induces a potent antitumor effect an

85 ns (IFN-I) are critical in antimicrobial and antitumor defense.

86 process, and effective targeted delivery of antitumor drugs is demonstrated.

87 ressing antitumor cytokines induces a potent antitumor effect and antitumor immunity by ameliorating

88 On their own, HDPDL1 exhibited no antitumor effect and CAd-VECPDL1 alone reduced tumors on

89 The secondary endpoints were antitumor effect and safety (UMIN000009446).

90 ion of SPIO-DOX and IRE demonstrate enhanced antitumor effect as compared with individual treatments

91 lines and primary specimens and had a robust antitumor effect in a disseminated MM mouse model.

92 Although the antitumor effect of anti-CD40/CpG did not require T cell

93 f anti-CD40/CpG did not require T cells, the antitumor effect of IC/anti-CTLA-4 was dependent on T ce

94 e we show that cGAS is indispensable for the antitumor effect of immune checkpoint blockade in mice.

95 nanosheets, showing a promising and enhanced antitumor effect.

96 F mutation rather than showing a synergistic antitumor effect.

97 dings identify CD56bright NK cells as potent antitumor effectors that warrant further investigation a

98 B13 exerted its anti-invasive and antitumor effects against prostate cancer cells, with mi

99 antimetastatic activity but lost its direct antitumor effects due to kinome reprogramming, which res

100 city (GI50 0.55 +/- 0.04 microM) and in vivo antitumor effects in a MIA PaCa-2 xenograft mouse model.

101 amatically potentiated the drugs' individual antitumor effects in a mouse model of breast cancer.

102 IRB) cells, which displayed superior in vivo antitumor effects in mice.

103 human cancers, potentially neutralizing the antitumor effects of calcitriol, the active form of vita

104 Here, we report the cellular and antitumor effects of CFI-402257, a potent (Mps1 Ki = 0.0

105 The antitumor effects of chemotherapies can in part be due t

106 r heterogeneity, in order to interrogate the antitumor effects of EGFR-targeted drugs in mCRC (n = 40

107 ed induction of MCP-1, implicating it in the antitumor effects of IgE.

108 Its overexpression can overcome the antitumor effects of miR-1 and promote androgen-independ

109 ylation in uterine epithelial cells, and the antitumor effects of P4 are mediated by the endometrial

110 e or antibiotic-treated mice ameliorated the antitumor effects of PD-1 blockade, whereas FMT from non

111 The potent antitumor effects of PPD/polyIC should spur its developm

112 osphorylation of certain RTKs, restoring the antitumor effects of sunitinib in models of acquired or

113 T-oligo can form a G-quadruplex and that the antitumor effects of T-oligo may be mediated through POT

114 of cGAMP and PD-L1 antibody exerted stronger antitumor effects than did either treatment alone.

115 These antitumor effects were reversed upon reconstitution with

116 posed antitumor mechanisms, in vivo reported antitumor effects, and possible mechanisms that may expl

117 tors of systemic immune responses, including antitumor effects, we hypothesized that components of th

118 h pathway cross-talk and display synergistic antitumor effects.

119 -2, can activate T and NK cells resulting in antitumor effects.

120 ntly been shown to lead to both protumor and antitumor effects.

121 of SHH-subtype medulloblastoma exerts potent antitumor effects.

122 od mononuclear cells or T cells enhanced the antitumor efficacy achieved by the parental counterpart.

123 reprogramming of T cells to achieve superior antitumor efficacy and even complete cures.

124 Similar in vivo antitumor efficacy and intratumoral CD8(+)/regulatory T

125 (DOX)-loaded SNP (SNP/DOX) shows significant antitumor efficacy and nearly eradicates the tumor, subs

126 combination is expected to have synergistic antitumor efficacy and significant potential for the tre

127 unization with DNA and Ad5 produced superior antitumor efficacy associated with increased TCR avidity

128 We demonstrate superior antitumor efficacy for IgE compared with an otherwise id

129 strategies attempts to decouple the observed antitumor efficacy from the on-target liver toxicity.

130 in well-characterized mouse models in which antitumor efficacy has been shown; inhibiting only late

131 rgeting these nodes concurrently resulted in antitumor efficacy in a majority of cetuximab-resistant

132 y, sustained multi-drug exposure, and potent antitumor efficacy in an ES-2-luc, ovarian cancer i.p. x

133 duced serious diarrhea while maintaining the antitumor efficacy in tumor-bearing mice.

134 be synergistic with phototherapy to improve antitumor efficacy in vitro and in vivo, offering a new

135 ockdown of NAC1 expression can reinforce the antitumor efficacy of bevacizumab, an inhibitor of angio

136 t and depleting properties contribute to the antitumor efficacy of CD27-targeted immunotherapy, and m

137 important obstacle to the evaluation of the antitumor efficacy of immunomodulator Abs in syngeneic m

138 ating peptide improves tumor selectivity and antitumor efficacy of IP pro-apoptotic NWs.

139 This study aims at characterizing the antitumor efficacy of sesamol and unveiling the importan

140 ggested by previous studies to have superior antitumor efficacy on various solid tumors.

141 Antitumor efficacy required stringent Treg depletion com

142 tial immunization with DNA and Ad5 maximized antitumor efficacy through TCR avidity enhancement, it p

143 Antitumor efficacy was demonstrated for (E1)-3s coadmini

144 SERD), exhibiting good oral bioavailability, antitumor efficacy, and SERD activity in vivo.

145 o, we show enhanced expansion and CAR T cell antitumor efficacy, culminating in improvement in surviv

146 rime or prime-boost regimens correlated with antitumor efficacy, whereas T cell number and cytokine p

147 f ATR have been reported showing significant antitumor efficacy, with most advanced ones entering cli

148 idity enhancement eliminated GUCY2C-specific antitumor efficacy, without affecting responding T cell

149 and adaptive immunity will result in better antitumor efficacy.

150 lue of (89)Zr-bevacizumab PET for everolimus antitumor efficacy.

151 duced neutropenia and anemia while retaining antitumor efficacy.

152 uppressive immune-modulating agents (IMs) on antitumor efficacy.

153 ting that sequential schedules could improve antitumor efficacy.

154 mcitabine as an optimal protocol to maximize antitumor efficacy.

155 ity, which has been associated with superior antitumor efficacy.

156 Our findings demonstrate enhancement of ZnPc antitumor efficiency by FF conjugates and a proof-of-con

157 We previously reported that glycosylated antitumor ether lipids (GAELs) display potent activity a

158 cally inert l-glucosamine-based glycosylated antitumor ether lipids (L-GAELs) that retain the cytotox

159 onjugated to a stabilized dimer of different antitumor Fabs.

160 Because of insufficient migration and antitumor function of transferred T cells, especially in

161 ransgenic T cells, c-MPL activation enhances antitumor function, T-cell expansion, and cytokine produ

162 es in HCCs and to find ways to restore their antitumor functions.

163 inomycin B (AZB), a potent antimicrobial and antitumor genotoxin.

164 Antitumor GO peptides have been designed as dimerization

165 r metabolism is associated with CD8-dominant antitumor immune infiltrate, and together, these contrib

166 mportant and previously unknown mechanism of antitumor immune regulation and provide new insights int

167 apeutics in tumor tissue and induce a potent antitumor immune response for an extended time period vi

168 ortant role in PD-1/PD-L1 regulation and the antitumor immune response of HNSCC.

169 Strategies that enhance the host antitumor immune response promise to revolutionize cance

170 d by NPM-ALK are also involved in evasion of antitumor immune response, protection from hypoxia, angi

171 fer cells and endothelial cells inhibits the antitumor immune response.

172 hibitors (CPIs), antibodies that unleash the antitumor immune response.

173 These mice are also defective for antitumor immune responses and are resistant to treatmen

174 vestigated the role of GITR agonism in human antitumor immune responses and report here the preclinic

175 dritic cells (DCs) required for induction of antitumor immune responses and success of cancer immunot

176 us be possible to use immuno-PET and monitor antitumor immune responses as a prognostic tool to predi

177 ponses to dead cells and to induce effective antitumor immune responses during anti-PD-1 treatment in

178 n several cancer histologies, reinvigorating antitumor immune responses in a subset of patients.

179 ory loop that may account for suppression of antitumor immune responses in glioblastoma.

180 er, the molecular factors that could empower antitumor immune responses in this setting remain to be

181 apies and for studying how they elicit human antitumor immune responses in vivo.

182 Clinically, PD-1 blockade elicits potent antitumor immune responses, and antibodies blocking PD-1

183 VA-5T4 each independently induced beneficial antitumor immune responses, resulting in prolonged survi

184 envisaging strategies aimed at facilitating antitumor immune responses.

185 to use oncolytic viruses to induce secondary antitumor immune responses.

186 sor cells (MDSCs), which actively suppressed antitumor immune responses.

187 NF-kappaB) that mediates innate and adaptive antitumor immune responses.

188 cancer in part by effects on DNA repair and antitumor immune responses.

189 and cancer cells, where it can downregulate antitumor immune responses.

190 lishment of premetastatic niches and inhibit antitumor immune responses.

191 hocyte proliferation and tumor cell-specific antitumor immune responses.

192 n of the chemokine CXCL14 and suppression of antitumor immune responses.

193 MicroRNA-155 (miR-155) regulates antitumor immune responses.

194 n is necessary for successful antiviral, and antitumor immune responses.

195 e immune surveillance is required to enhance antitumor immune responses.

196 negative regulator of NK-cell maturation and antitumor immune responses.

197 ey mechanism by which tumor PD-L1 suppresses antitumor immunity and demonstrate that tumor PD-L1 is n

198 o promote natural killer cell maturation and antitumor immunity and reduce tumor growth.

199 the cGAS pathway is important for intrinsic antitumor immunity and that cGAMP may be used directly f

200 B16 tumors, greatly enhanced nutlin-induced antitumor immunity and tumor control.

201 trating leukocytes (TILeus) induces systemic antitumor immunity and tumor regression, but not in TME

202 okines induces a potent antitumor effect and antitumor immunity by ameliorating the immunosuppressive

203 Consequently, antitumor immunity by CD8(+) T cells that display defect

204 We examined expression of antitumor immunity genes across subtypes to uncover biom

205 on nontumor cells is critical for inhibiting antitumor immunity in B16 melanoma and a genetically eng

206 Hodgkin Reed-Sternberg (HRS) cells to evade antitumor immunity in classical Hodgkin lymphoma (cHL).

207 nhibitor with standard therapy could improve antitumor immunity in GBM.

208 ocyte-associated protein 4 (CTLA-4) restored antitumor immunity in miR-155 T cell-conditional KO mice

209 tibodies that block these receptors increase antitumor immunity in patients with melanoma, non-small-

210 Successful antitumor immunity is thought to require T cell entry in

211 Tumor exosomes are emerging as antitumor immunity regulators; however, their effects on

212 bicin can contribute to re-establishing host antitumor immunity through the generation of immunogenic

213 ivation, dendritic cell (DC) maturation, and antitumor immunity through the photoactivation of engine

214 nti-PD-L1, because it was assumed that their antitumor immunity was compromised compared with immunoc

215 Mechanistically, nutlin-3a-induced antitumor immunity was contingent on two nonredundant bu

216 arness tumor-specific, durable, and systemic antitumor immunity with minimal toxicity.

217 opment of allospecific transplant tolerance, antitumor immunity, and cross-generational reproductive

218 enocarcinoma cells is sufficient to suppress antitumor immunity, as deletion of PD-L1 on highly immun

219 e investigations of early stages of adaptive antitumor immunity, as well as support the rationale for

220 suppression within the tumor, and reactivate antitumor immunity, but they have yet to live up to thei

221 PPD/polyIC invokes antitumor immunity, but unlike many immunotherapies does

222 ent DCs are critical determinants for T cell antitumor immunity, effector T cell trafficking to the t

223 were associated with increased expression of antitumor immunity, including activation of CD8-positive

224 licited by multiple 'targeted' inhibitors on antitumor immunity, underscoring the complex effects res

225 dies can lead to tumor clearance and durable antitumor immunity.

226 nment is known to inhibit effective adaptive antitumor immunity.

227 mmunogenic MC38 tumor cells allows effective antitumor immunity.

228 D47-SIRPalpha axis is critical for DC-driven antitumor immunity.

229 rug in its ability to productively stimulate antitumor immunity.

230 of miR-155 in T cells, in which it promotes antitumor immunity.

231 mor PD-L1 is not just a marker of suppressed antitumor immunity.

232 ance could lead to new strategies to enhance antitumor immunity.

233 icit poorly understood effects on protective antitumor immunity.

234 overcoming TGF-beta1-induced suppression of antitumor immunity.

235 article formulation of doxorubicin, enhances antitumor immunity.

236 he former of which are superior in mediating antitumor immunity.

237 pansion reduces memory potential and impairs antitumor immunity.

238 induce long-lasting CD8(+) T cell-dependent antitumor immunity.

239 n the presence of spontaneous or therapeutic antitumor immunity.

240 comes, credited to their ability to suppress antitumor immunity.

241 onstrated evidence of durable tumor-specific antitumor immunity.

242 ICB regulate overlapping pathways to promote antitumor immunity.

243 utic benefits by augmenting NK cell-mediated antitumor immunity.Significance: Ablating adenosine sign

244 n of Ezh2 as a critical target to potentiate antitumor immunotherapeutic strategies.

245 Our study strongly argues for the use of antitumor immunotherapies combined with nanoparticle-pac

246 onses as a potential biomarker for effective antitumor immunotherapy and support a formal assessment

247 -cell responses as a biomarker for effective antitumor immunotherapy.

248 enhanced recruitment of innate immune cells (antitumor macrophages, natural killer cells) associated

249 delay correlated with increased infiltrating antitumor macrophages.

250 d within their stroma CD8(+) T cells and M1 (antitumor) macrophages.

251 The present Perspective analyses proposed antitumor mechanisms, in vivo reported antitumor effects

252 manifests more favorable pharmacokinetic and antitumor pharmacodynamic profiles in vivo than that of

253 arized intratumoral myeloid cells towards an antitumor phenotype.

254 reveal multiple unrecognized features of the antitumor properties of oncolytic vaccinia viruses, all

255 To assess the antitumor properties of QC6352, we established a method

256 They show antitumor properties.

257 d that AMC extract exhibited antioxidant and antitumor properties.

258 type 2, away from the type 1 mechanisms with antitumor properties.

259 Patients with ALL, >/=4 prior antitumor regimens, and receipt of the highest CAR-T-cel

260 of KRAS status, cetuximab did not induce an antitumor response in a majority of patient tumors.

261 essing targets in vivo, and elicits a better antitumor response in a model of E7-expressing lung canc

262 re without toxicity but induced insufficient antitumor response in these high-tumor-burden patients.

263 ief priming with IL-15 markedly enhanced the antitumor response of CD56bright NK cells.

264 Finally, with the aim of increasing the antitumor response of perioperative RT, these agents may

265 immune-activating signals and maintains the antitumor response, has elicited a remarkable clinical r

266 g lymphocytes (TILs) indicates an endogenous antitumor response, immune regulatory pathways can subve

267 u-DOTATATE treatment and induces a prolonged antitumor response.

268 ntial for generating durable and synergistic antitumor response.

269 ceptor expressed by lymphocytes, in limiting antitumor responses and we review its mechanisms of acti

270 ereas in cancer, T cells are unable to mount antitumor responses due to the Treg-enriched suppressive

271 bacterial infections can produce efficacious antitumor responses in mice, rats, dogs, and humans.

272 CD8alpha:MyD88-expressing T cells improved antitumor responses in mice.

273 dified (CAR) T cells has produced impressive antitumor responses in patients with refractory CD19(+)

274 acute stimulation, resulting in impaired NK antitumor responses in vivo.

275 in BVE(Cyp24a1-null) cells, it strengthened antitumor responses to the BRAF(V600E) inhibitor PLX4720

276 ally providing an approach to achieve potent antitumor responses while minimizing ADC-induced toxicit

277 CD56dim NK cell subset is thought to mediate antitumor responses, whereas the CD56bright subset is in

278 an be activated to induce long-term, durable antitumor responses.

279 s, and blockade of these pathways attenuated antitumor responses.

280 ng AML-specific antibodies may contribute to antitumor responses.

281 CAR T-cell therapy would result in improved antitumor responses.

282 ligand fusion proteins, produced synergistic antitumor responses.

283 y during viral, intracellular bacterial, and antitumor responses.

284 sion of immune inhibitory ligands to inhibit antitumor T cell function.

285 lish spontaneous and PD-L1-blockade-mediated antitumor T cell immunity.

286 pproach to elucidate the global landscape of antitumor T cell responses in complete regression of hum

287 by tumor cells potently inhibits endogenous antitumor T cell responses through activation of adenosi

288 tosis-sensitizing cytokines and promotion of antitumor T cell responses.

289 eting RPS19 for anticancer therapy enhancing antitumor T cell responses.

290 or growth; this was accompanied by augmented antitumor T- and B-cell responses and decreased infiltra

291 lonal antibodies (mAbs) able to reinvigorate antitumor T-cell immunity have heralded a paradigm shift

292 more, it was associated with more pronounced antitumor T-cell immunity via induction of IL17 and IFNg

293 Purpose Ipilimumab increases antitumor T-cell responses by binding to cytotoxic T-lym

294 neered to express an MHC class II-restricted antitumor TCR that targets MAGE-A3.

295 nsfer, enhancing their survival and also the antitumor therapeutic activity of a tumor-specific pepti

296 playing Affibody ligands exhibit much better antitumor therapeutic outcomes than clinically approved

297 portunities for the development of effective antitumor therapies.

298 ceptor 3 (HER3) is an interesting target for antitumor therapy.

299 active tumor targeting signal and enhancing antitumor therapy.

300 ion for the development of splicing-directed antitumor treatments and supports the potential of USP39